Moreover, when the GLP-1 receptor agonist, exenatide, was administered with a concurrent intraduodenal glucose infusion in T2D, blood pressure and heart rate increased rather than decreased, when compared to control [82]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.